{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:12:53Z","timestamp":1790766773373,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"am","delay-in-days":405,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bulcan.2019.12.005","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T08:17:13Z","timestamp":1579594633000},"page":"54-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Le protocole FLOT est-il le nouveau standard de chimioth\u00e9rapie p\u00e9ri-op\u00e9ratoire des cancers de l\u2019estomac\u00a0?"],"prefix":"10.1016","volume":"107","author":[{"given":"Antoine","family":"Adenis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Samalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Mazard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Portales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Mourregot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ychou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bulcan.2019.12.005_bib0125","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2019.12.005_bib0130","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.dld.2018.04.025","article-title":"Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)","volume":"50","author":"Zaanan","year":"2018","journal-title":"Dig Liver Dis"},{"issue":"12","key":"10.1016\/j.bulcan.2019.12.005_bib0135","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJM199903253401202","article-title":"Extended lymph-node dissection for gastric cancer","volume":"340","author":"Bonenkamp","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2019.12.005_bib0140","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(10)70070-X","article-title":"Surgical treatment of gastric cancer: 15-year follow-up results of the randomized nationwide Dutch DD trial","volume":"11","author":"Songun","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2019.12.005_bib0145","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","article-title":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","volume":"345","author":"MacDonald","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2019.12.005_bib0150","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.2010.534","article-title":"Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis","volume":"303","author":"The Gastric Group","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2019.12.005_bib0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.bulcan.2019.12.005_bib0160","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1200\/JCO.2013.54.1011","volume":"32","author":"Ychou","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2019.12.005_bib0165","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatine for advanced oesophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2019.12.005_bib0170","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO clinical practice guidelines for diagnostic, treatment, and follow-up","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2019.12.005_bib0175","volume":"35","author":"Al-Batran","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2019.12.005_bib0180","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bulcan.2019.12.005_bib0185","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"Al-Batran","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2019.12.005_bib0190","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1470-2045(17)30043-8","article-title":"Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3\u00a0trial","volume":"18","author":"Cunningham","year":"2017","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.bulcan.2019.12.005_bib0195","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bulcan.2019.12.005_bib0200","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2019.12.005_bib0205","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s12885-016-2564-y","article-title":"ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)","volume":"16","author":"Hoeppner","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bulcan.2019.12.005_bib0210","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12885-017-3386-2","article-title":"ICORG 10-14: neoadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)","volume":"17","author":"Reynolds","year":"2017","journal-title":"BMC Cancer"},{"issue":"31","key":"10.1016\/j.bulcan.2019.12.005_bib0215","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325\u00a0Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2019.12.005_bib0220","doi-asserted-by":"crossref","first-page":"15806","DOI":"10.1038\/s41598-019-52334-y","article-title":"Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors","volume":"9","author":"Uson Junior","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.bulcan.2019.12.005_bib0225","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/bjc.2012.588","article-title":"Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advances esophagogastric cancer","volume":"108","author":"Lorenzen","year":"2013","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2019.12.005_bib0230","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/COC.0000000000000271","article-title":"A phase I\/II study of docetaxel, oxaliplatin, and fluorouracil (D-FOX) chemotherapy in patients with untreated locally unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction","volume":"41","author":"Blum Murphy","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2019.12.005_bib0235","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41416-018-0133-7","article-title":"Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study","volume":"119","author":"Pernot","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2019.12.005_bib0120","first-page":"1255","article-title":"The effect of an individual's cytochrome CYP3A4\u00a0activity on docetaxel clearance","volume":"6","author":"Hirth","year":"2000","journal-title":"Clin Cancer Res"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120300023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120300023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:31:47Z","timestamp":1757791907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455120300023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0007455120300023"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.12.005","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Le protocole FLOT est-il le nouveau standard de chimioth\u00e9rapie p\u00e9ri-op\u00e9ratoire des cancers de l\u2019estomac\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}